Head and Neck Cancer Trial, Recruiting NCT06686979 Sponsor: Huashan Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06686979
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with recurrent or metastatic salivary gland cancer, confirmed by a laboratory test on a tissue sample.
  • People who have tumour tissue available that can be used to grow cancer cell cultures for the study.
  • People whose general health and ability to carry out daily activities falls within an acceptable range (based on a standard medical scoring system, rated 0–2 out of 5).
  • People whose doctors estimate they are likely to live for more than 3 months.
  • People whose blood cell counts, liver function, kidney function, and blood clotting levels all fall within acceptable ranges as measured by recent lab tests (confirm with trial site for specific values required).

Who may not be able to join:

  • People whose cancer originated somewhere other than the salivary glands, including certain cancers that have spread to the head and neck area, or cancers such as sarcoma, squamous cell carcinoma, or nasopharyngeal carcinoma.
  • People who are known to be allergic to any of the study drugs, their ingredients, or who have had a severe allergic reaction to other similar medicines (called monoclonal antibodies).
  • People who are pregnant, breastfeeding, or who test positive for pregnancy within 7 days before joining the trial.
  • Women of childbearing age who test negative for pregnancy but are unwilling to use effective contraception throughout the study and for 2 months after the last dose.
  • Male participants with partners who could become pregnant, who are unwilling to use effective contraception throughout the study and for 2 months after the last dose.
  • People with severe or uncontrolled diseases affecting the liver, kidneys, lungs, blood, or hormonal (endocrine) system.
  • People who have HIV, active hepatitis B, or hepatitis C that is not controlled.
  • People who have had a heart attack, severe chest pain, significant heart failure, serious abnormal heart rhythms, or uncontrolled heart problems in the 6 months before joining the trial.
  • People with a mental illness, or a known history of misusing psychiatric drugs or other substances.
  • People who are unable to give informed consent or from whom the required amount of tumour tissue cannot be obtained.
  • People with other serious physical or mental health conditions, abnormal lab results, or any other circumstances that the research team considers would make participation unsuitable or unsafe.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lai-ping Zhong, MD, PhD, Huashan Hospital

Phone: +862152888915

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Huashan Hospital
Registry
ClinicalTrials.gov
Start date
26 March 2025
Est. completion
30 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate; Disease Control Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov